CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Savara Inc (SVRA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Savara Inc (SVRA)

Pharmaceutical Preparations · market cap $1.0B · as of 2026-11-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-22
PDUFA
Pipeline
6
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Savara Inc (SVRA) is a ~$992M market-cap company (~205.5M shares at ~$4.83) with no revenue in 2021–2025. Its value is concentrated in its lead asset, molgramostim, for autoimmune pulmonary alveolar proteinosis (aPAP), which has a PDUFA date of 2026-11-22, two weeks from this note. Reported cash is $41.8M with a stated 17.5-month runway, and our data flags dilution risk as elevated (34%).
The catalyst path
  • 2026-11-22PDUFA · Molgramostimimp 9/10
  • 2027-06-15 (est.)Phase 3 · Molgramostimimp 9/10
Pipeline
AssetPhaseIndication
Inhaled molgramostimPhase 2Mycobacterium Infections, Nontuberculous
MolgramostimPhase 3Autoimmune Pulmonary Alveolar Proteinosis
Vancomycin hydrochloride inhalation powderPhase 2Cystic Fibrosis
Vancomycin inhalation powderPhase 3MRSA
Antimycobacterial regimenPhase 2Mycobacterium Infections, Nontuberculous
Molgramostim Open-labelPhase 3Autoimmune Pulmonary Alveolar Proteinosis
Price & technical context
3-month
-15.3%
6-month
-7.3%
12-month
+6.8%
52-wk range
$4.17–$6.94
vs 50-day MA
-7.5%
vs 200-day MA
-14.6%
Realized vol
54.2%
Max drawdown
-52.3%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for SVRA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.